Allergy Therapeutics plc
LSE AGY.L
Allergy Therapeutics plc Net Cash Used For Investing Activities for the year ending June 30, 2024: USD -1.52 M
-
Allergy Therapeutics plc Net Cash Used For Investing Activities for the year ending June 30, 2023 was USD -5.93 M, a -59.28% change year over year.
-
Allergy Therapeutics plc Net Cash Used For Investing Activities for the year ending June 30, 2022 was USD -3.72 M, a 2.37% change year over year.
-
Allergy Therapeutics plc Net Cash Used For Investing Activities for the year ending June 30, 2021 was USD -3.81 M, a -10.76% change year over year.
-
Allergy Therapeutics plc Net Cash Used For Investing Activities for the year ending June 30, 2020 was USD -3.44 M, a 19.17% change year over year.
| Date | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities | Dividends Paid | Capital Expenditure |
|---|
| CEO | Mr. Manuel Llobet |
| IPO Date | Oct. 11, 2004 |
| Location | United Kingdom |
| Headquarters | Dominion Way |
| Employees | 612 |
| Sector | Health Care |
| Industries | |
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email